Key result
Initiating antihypertensive therapy with a fixed low-dose combination of perindopril and indapamide normalized blood pressure in 62% of patients, compared to 49% with sequential monotherapy.
Why the study?
Does a fixed low-dose combination of perindopril and indapamide improve blood pressure normalization compared to sequential monotherapy or stepped-care strategies in hypertensive patients?
Does a fixed low-dose combination of perindopril and indapamide improve blood pressure normalization compared to sequential monotherapy or stepped-care strategies in hypertensive patients?
Fixed low-dose combination therapy with perindopril and indapamide is more effective than sequential monotherapy or stepped-care strategies for achieving blood pressure targets in high-risk hypertensive patients.
Answers are grounded in this paper and cite their sources.
Supports starting with fixed low-dose perindopril-indapamide; leaves open effects on cardiovascular outcomes versus sequential strategies.
Pharmacological treatment of hypertension represents a cost-effective way of preventing cardiovascular and renal complications. To benefit maximally from antihypertensive treatment, blood pressure should be brought to below 140/90 mmHg in every hypertensive patient, and even lower (< 130/80 mmHg) if diabetes or renal disease co-exists. Such targets cannot usually be reached using monotherapies. This is especially true in patients who present with a high cardiovascular risk. The co-administration of two agents acting by different mechanisms considerably increases the blood pressure control rate. Such combinations are not only efficacious, but are also well tolerated, and some fixed low-dose combinations even have a placebo-like tolerability. This is the case for the preparation containing the angiotensin-converting enzyme inhibitor perindopril (2 mg) and the diuretic indapamide (0.625 mg), a fixed low-dose combination that has been shown in controlled trials to be more effective than monotherapies in reducing albuminuria, regressing cardiac hypertrophy and improving the stiffness of large arteries. Using this combination to initiate antihypertensive therapy has been shown in a double-blind trial (Strategies of Treatment in Hypertension: Evaluation; STRATHE) to normalize blood pressure (< 140/90 mmHg) in significantly more patients (62%) than a sequential monotherapy approach based on atenolol, losartan and amlodipine (49%) and a stepped-care strategy based on valsartan and hydrochlorothiazide (47%), with no difference between the three arm groups in terms of tolerability. An ongoing randomized trial (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation; ADVANCE) is a study with a 2 x 2 factorial design assessing the effects of the fixed-dose perindopril-indapamide combination and of the intensive gliclazide modified release-based glucose control regimen in type 2 diabetic patients, with or without hypertension. A total of 11 140 patients were randomly selected. Within the first 6 weeks of treatment (run-in phase), the perindopril-indapamide combination lowered blood pressure from 145/81 +/- 22/11 mmHg (mean +/- SD) to 137/78 +/- 20/10 mmHg. Fixed-dose combinations are becoming more and more popular for the management of hypertension, and are even proposed by hypertension guidelines as a first-line option to treat hypertensive patients.
No takes yet. Share an insight, caveat, or question.
Bernard Waeber (2006) conducted a review in Hypertension and Type 2 Diabetes (n=11,140). Perindopril-indapamide fixed low-dose combination vs. Sequential monotherapy (atenolol, losartan, amlodipine) or stepped-care strategy (valsartan, hydrochlorothiazide) was evaluated on Blood pressure normalization (< 140/90 mmHg). Initiating antihypertensive therapy with a fixed low-dose combination of perindopril and indapamide normalized blood pressure in 62% of patients, compared to 49% with sequential monotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: